<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03867604</url>
  </required_header>
  <id_info>
    <org_study_id>N201811013</org_study_id>
    <nct_id>NCT03867604</nct_id>
  </id_info>
  <brief_title>Ultrasound-guided Fascial Release Injection for Myofascial Pain Syndrome in the Upper Trapezius Muscle</brief_title>
  <official_title>Ultrasound-guided Fascial Release Injection for Myofascial Pain Syndrome in the Upper Trapezius Muscle: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taipei Medical University WanFang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taipei Medical University WanFang Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with myofascial pain syndrome at upper trapezius will be randomized into 2 groups,
      fascial injection group and subcutaneous control injection group. Pain condition pain, range
      of motion and function will be evaluated in 1 week, 4 weeks and 12 weeks after injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Myofascial pain syndrome(MPS) is characterized by a trigger point with a hyperirritable
      nodule and taut band of muscle or fascia. MPS was usually treated by dry needling or met
      needing, local anesthetics injection, to the trigger point. According to recent researches,
      dry and wet needling to affected muscle are effectiveness for short term and medium term pain
      relief. Although some researches indicated an increased viscosity at fascial layer in MPS and
      there are few studies of manipulation for fascial release. There is not study of injective
      fascial release.

      Investigators will include 40 patients with myofascial pain syndrome at upper trapezius.
      Participants will be randomized into 2 groups, fascia injection group and subcutaneous
      control injection group. Investigators will use algometer to measure pain threshold and peak
      pressure, measure the range of motion of neck and shoulder and assess the neck and shoulder
      function by questionnaire. The examination will be done before injection, immediately after
      injection, 1 week, 4 weeks and 12 weeks after injection.

      To our hypothesis, investigators suggest focal anesthetics injection could decrease the
      fascial viscosity and improved pain and quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 17, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Upper back or shoulder pain</measure>
    <time_frame>Change from baseline VAS at 1 week</time_frame>
    <description>visual analogue scale(VAS), range 0-10, the higher the worse pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Upper back or shoulder pain</measure>
    <time_frame>Change from baseline VAS at 4 week</time_frame>
    <description>visual analogue scale(VAS), range 0-10, the higher the worse pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Upper back or shoulder pain</measure>
    <time_frame>Change from baseline VAS at 12 week</time_frame>
    <description>visual analogue scale(VAS), range 0-10, the higher the worse pain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Function</measure>
    <time_frame>Change from baseline SPADI at 1 week</time_frame>
    <description>Shoulder Pain and Disability Index (SPADI), range 0-130, the higher the worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function</measure>
    <time_frame>Change from baseline SPADI at 4 week</time_frame>
    <description>Shoulder Pain and Disability Index (SPADI), range 0-130, the higher the worse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function</measure>
    <time_frame>Change from baseline SPADI at 12 week</time_frame>
    <description>Shoulder Pain and Disability Index (SPADI), range 0-130, the higher the worse</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Myofascial Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Sham injection</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Subcutaneous injection at upper trapezium muscle level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fascia injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fascia injection, below upper trapezium muscle</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham injection</intervention_name>
    <description>Injection to the subcutaneous layer at upper trapezium level</description>
    <arm_group_label>Sham injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fascia injection</intervention_name>
    <description>Injection to the fascia below upper trapezium muscle</description>
    <arm_group_label>Fascia injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  20-70 years old

          -  diagnosed as a myofascial pain syndrome at upper trapezium muscle

          -  trigger point

          -  taut band

          -  refer pain while taut band irritation

        Exclusion Criteria:

          -  Cognitive impairment.

          -  Post operation at neck and shoulder.

          -  Nerve compression at cervical region.

          -  Could not receive injection therapy, history of fainting during needling
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu-Hsuan Cheng, Cheng</last_name>
    <role>Study Director</role>
    <affiliation>Taipei Medical University, Taiwan, R.O.C.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu-Hsuan Cheng, MS</last_name>
    <phone>+886 229307930</phone>
    <phone_ext>1600</phone_ext>
    <email>heathcyh@gmail.com</email>
  </overall_contact>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>March 6, 2019</last_update_submitted>
  <last_update_submitted_qc>March 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

